These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36252317)
1. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Chen JJ; Flanagan EP; Bhatti MT; Tisavipat N; Jamali S; Kunchok A; Eggenberger ER; Nome MD; Sotirchos ES; Vasileiou ES; Henderson AD; Arnold AC; Bonelli L; Seleme N; Mejia-Vergara AJ; Moss HE; Padungkiatsagul T; Stiebel-Kalish H; Lotan I; Wilf-Yarkoni A; Hellmann MA; Vuppala A; Hodge D; Pittock SJ Mult Scler Relat Disord; 2022 Dec; 68():104237. PubMed ID: 36252317 [TBL] [Abstract][Full Text] [Related]
2. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Stiebel-Kalish H; Hellmann MA; Mimouni M; Paul F; Bialer O; Bach M; Lotan I Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e572. PubMed ID: 31355308 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes. Min YG; Moon Y; Kwon YN; Lee BJ; Park KA; Han JY; Han J; Lee HJ; Baek SH; Kim BJ; Kim JS; Park KS; Kim NH; Kim M; Nam TS; Oh SI; Jung JH; Sung JJ; Jang MJ; Kim SJ; Kim SM J Neurol Neurosurg Psychiatry; 2024 Jul; 95(8):753-760. PubMed ID: 38418215 [TBL] [Abstract][Full Text] [Related]
13. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199 [TBL] [Abstract][Full Text] [Related]
14. Clinical profile and challenges faced in the management of optic neuritis: the Indian scenario. Kaushik M; Shah VM; Murugesan S; Mani KK; Vardharajan S Int Ophthalmol; 2024 Mar; 44(1):138. PubMed ID: 38488890 [TBL] [Abstract][Full Text] [Related]
15. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. Stiebel-Kalish H; Lotan I; Brody J; Chodick G; Bialer O; Marignier R; Bach M; Hellmann MA PLoS One; 2017; 12(1):e0170847. PubMed ID: 28125740 [TBL] [Abstract][Full Text] [Related]
17. Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: The importance of age of onset and prognosis-related radiological features. Zhao J; Chen X; Zhang J; Liu L; Wang J; Zhu L Mult Scler Relat Disord; 2024 May; 85():105518. PubMed ID: 38447395 [TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of first-ever episode of severe optic neuritis. Galetta K; Ryan S; Manzano G; Chibnik LB; Balaban D; Prasad S; Chwalisz BK; Salazar-Camelo A; Conway S; Levy M; Matiello M Mult Scler Relat Disord; 2022 Oct; 66():104020. PubMed ID: 35839615 [TBL] [Abstract][Full Text] [Related]
19. Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment. Vosoughi AR; Micieli JA Mult Scler Relat Disord; 2020 Nov; 46():102456. PubMed ID: 32853896 [TBL] [Abstract][Full Text] [Related]
20. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan. Ishikawa H; Kezuka T; Shikishima K; Yamagami A; Hiraoka M; Chuman H; Nakamura M; Hoshi K; Goseki T; Mashimo K; Mimura O; Yoshitomi T; Tanaka K; Ophthalmology; 2019 Oct; 126(10):1385-1398. PubMed ID: 31196727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]